MRC1 and breast neoplasm: In the same study, the specific targeting of CYP4A using pharmacological approaches in 4T1 breast tumor-bearing mice reprogrammed tumor-infiltrated TAMs with a F4/80+CD206+ phenotype into TAM with a F4/80+iNOS+ “anti-tumor” phenotype, and reduced lung metastatic burden by impairing the preparation of the pre-metastatic niches (39).